Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Posts Q3 Revenue Rise

SAN FRANCISCO, Oct. 23 – Cepheid on Tuesday posted third-quarter revenues of $2.8 million versus $2.3 for the same quarter a year ago, the company announced.

For the nine months ending September 30, 2001, revenue jumped 85 percent to $8.1 million compared to $4.4 million for the same period in 2000.

The company said the revenue increase was due to increased sales of its Smart Cycler DNA analysis systems, with sales increasing to $2 million from $1.6 million for the same quarter in 2000.

Cepheid, based in Sunnyvale, Calif., reported a net loss of $4.0 million, or 15 cents per share for the third quarter of 2001, compared to a net loss of $3.8 million, or 15 cents per share for the third quarter of 2000. 

As of September 30, 2001, the company had $29.7 million in cash and cash equivalents. 

Last week, Cepheid share price jumped due to interest in the company’s biothreat detection technology.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.